...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in endocrinology and metabolism. >The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective
【24h】

The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective

机译：从英国卫生保健系统的角度来看，速效门冬胰岛素与门冬胰岛素相比在大剂量胰岛素治疗糖尿病患者中的价值

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Fast-acting insulin aspart is a new formulation of the rapid-acting insulin analogue insulin aspart and represents an advancement over current rapid-acting insulin analogues in terms of onset of action and postprandial glucose control. The objective of the current analysis was to demonstrate the cost impact of prescribing fast-acting insulin aspart instead of insulin aspart, to highlight the value of fast-acting insulin aspart for the treatment of people with diabetes requiring mealtime insulin. A cost-impact analysis was conducted from the perspective of the UK National Health Service (NHS). The analysis excluded patients’ out-of-pocket expenses, carers’ costs and lost productivity. The time horizon of the analysis was 1 year, and no discounting was therefore applied. The displacement of insulin aspart with fast-acting insulin aspart is cost neutral for the UK NHS. Fast-acting insulin aspart is at price parity to insulin aspart in terms of the vial and Penfill? cartridge and is available in the FlexTouch? pen at the same price as the insulin aspart FlexPen? (and thus cheaper than the insulin aspart FlexTouch? pen). Patients using the insulin aspart FlexPen? will be upgraded to the FlexTouch? pen device, which is preferred by patients and healthcare professionals, on switching to fast-acting insulin aspart, at no additional cost. Fast-acting insulin aspart offers additional clinical benefit but at no additional cost when compared with insulin aspart, and thus provides value to the UK NHS.
机译：阿司匹林速效胰岛素是阿司匹林速效胰岛素类似物的新配方，在起效和餐后血糖控制方面代表了比目前速效胰岛素类似物的进步。当前分析的目的是证明处方速效胰岛素门冬胰岛素而不是门冬胰岛素的成本影响，强调速效门冬胰岛素在需要进餐时间胰岛素的糖尿病患者中的价值。从英国国家卫生服务局（NHS）的角度进行了成本影响分析。该分析不包括患者的自付费用，护理人员的费用和生产力损失。分析的时间范围为1年，因此未应用折现。对于英国NHS，使用速效胰岛素门冬氨酸替代胰岛素门冬氨酸是成本中立的。就小瓶和Penfill而言，速效门冬胰岛素的价格与门冬胰岛素的价格相等。墨盒，可以在FlexTouch中使用吗？笔价格与门冬胰岛素FlexPen相同？ （因此比天门冬胰岛素FlexTouch？笔便宜）。患者使用门冬胰岛素FlexPen？会升级到FlexTouch吗？在无需额外费用的情况下，患者和医疗保健专业人员首选的笔式设备即可转换为速效门冬胰岛素。速效门冬胰岛素可提供更多的临床益处，但与门冬胰岛素相比无需额外费用，因此可为UK NHS提供价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号